Inmed Pharmaceuticals Inc. (INM) has released an update.
InMed Pharmaceuticals Inc. has announced promising preclinical data for its drug INM-089, showing potential benefits in treating dry Age-Related Macular Degeneration (AMD). The treatment has exhibited improved retinal health and neuroprotection in preclinical models, aiming to address the significant unmet medical need for effective AMD therapies. INM-089, a small molecule compound, targets CB1/CB2 receptors, which play a crucial role in the endocannabinoid system and are key to maintaining retinal integrity and function.
For further insights into INM stock, check out TipRanks’ Stock Analysis page.
